Tacrolimus is commonly used for immunosuppression in patients following solid organ
transplantation. For transplant patients with COVID-19 infection, early treatment is indicated …

Since the onset of the SARS-CoV-2 (COVID-19) pandemic, significant effort has been
devoted toward developing therapeutics that decrease the morbidity and mortality of COVID …

To the Editor: A 41-year-old female patient with a history of renal transplant presented to the
emergency department with nausea, vomiting, and tremors. The patient had been …

Background Nirmatrelvir/ritonavir, a newly authorized drug for the treatment of COVID-19, is
a strong CYP3A4 inhibitor that can interact with many drugs, such as tacrolimus, reducing its …

Nirmatrelvir/ritonavir was recently granted emergency use authorization for mild to moderate
coronavirus disease 2019. Drug–drug interactions between ritonavir and tacrolimus are …

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has
had a significant impact on communities and health systems. New antiviral medications …

Nirmatrelvir is an orally administered anti-SARS-CoV-2 drug used in combination with
ritonavir, the drug-metabolizing cytochrome P450 (CYP) 3A inhibitor, to evade metabolism …

Background Solid organ transplant (SOT) recipients are at risk of complications from COVID‐
19. Nirmatrelvir/ritonavir (Paxlovid) can reduce mortality from COVID‐19 but is …

Objectives Nirmatrelvir/ritonavir may cause a clinically relevant drug-drug interaction (DDI)
with immunosuppressive drugs, such as tacrolimus, which may condition the use of this …

Background Tacrolimus toxicity in patient's status post-orthotropic heart transplantation is not
commonly reported. Given its narrow therapeutic window and drug–drug interactions, it must …